LORISTA H PILLS 50 MG + 12.5 MG
LORISTA H PILLS 50 MG + 12.5 MG - 30 TABS
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Lorista H coated tablets:
1 tab. contains Losartan potassium 50 mg, hydrochlorothiazide 12.5 mg;
Excipients: pregelatinized starch; MCC; lactose monohydrate; Magnesium stearate;
shell: hypromellose; macrogol 4000; quinoline yellow dye (E104); titanium dioxide (E171); talc;
Pack of 14, 30, 60 or 90 pcs.
Mechanism of action
Lorista H has a hypotensive effect.
Indications and usage
arterial hypertension (for patients who are recommended combination therapy);
reducing the risk of cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy.
Hypersensitivity to losartan, to agents derived from sulfonamides and other components of the drug, anuria, pronounced renal dysfunction (Cl creatinine <30 ml / min), hyperkalemia, dehydration (including while taking high doses of diuretics), expressed abnormal liver function, refractory hypokalemia, pregnancy, lactation, hypotension, age up to 18 years (efficacy and safety have not been established), lactase deficiency, galactosemia or malabsorption syndrome of glucose / galactose.
Carefully: disorders of water and electrolyte balance of the blood (hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypokalemia), bilateral renal artery stenosis or arterial stenosis of a single kidney, diabetes mellitus, hypercalcemia, hyperuricemia and / or gout, aggravated allergic anesthesia, development, arrest development, arrest development, arrhythmia, development, arrhythmia, development, arrhythmias, hyperuricemia, and / or gout. Drugs, including ACE inhibitors) and bronchial asthma, systemic blood diseases (including systemic lupus erythematosus), the simultaneous appointment of NSAIDs, including COX-2 inhibitors.
From the blood and lymphatic system: infrequently - anemia, Schönlein-Genoch disease.
Immune system: rarely, Anaphylactic reactions, angioedema (including swelling of the larynx and tongue, causing airway obstruction and / or swelling of the face, lips, pharynx).
Nervous system: often - headache, systemic and non-systemic dizziness, insomnia, fatigue; infrequently - migraine.
Cardiovascular: often - orthostatic hypotension (dose-dependent), palpitations, tachycardia; rarely - vasculitis.
Respiratory: often - cough, infections of the upper respiratory tract, pharyngitis, swelling of the nasal mucosa.
From the digestive tract: often - diarrhea, dyspepsia, nausea, vomiting, abdominal pain.
From the hepatobiliary system: rarely - hepatitis, abnormal liver function.
From the skin and subcutaneous fat: infrequently - urticaria, pruritus.
From the musculoskeletal system and connective tissue: often - myalgia, back pain; infrequently - arthralgia.
Other: often - asthenia, weakness, peripheral edema, chest pain.
Laboratory values: often - hyperkalemia, increased hemoglobin and hematocrit (clinically insignificant); sometimes a moderate increase in the level of urea and serum creatinine; very rarely - increased activity of liver enzymes and bilirubin.
Dosage and administration
Inside, regardless of the meal.
Lorista H can be combined with other antihypertensive drugs.
Arterial hypertension. Initial and maintenance dose - 1 table. Lorista H (50 / 12.5 mg) 1 time per day. The maximum antihypertensive effect is achieved within 3 weeks of therapy. To achieve a more pronounced effect, it is possible to increase the dose of the drug to 2 table. Lorista H (50 / 12.5 mg) 1 time per day. The maximum daily dose - 2 tablets. drug Lorista H.
In patients with reduced BCC (for example, when receiving large doses of diuretics), the recommended initial dose of losartan in patients with hypovolemia is 25 mg once a day. In this regard, the treatment of Lorista H should begin after the abolition of diuretics and the correction of hypovolemia.
In elderly patients and patients with moderate renal insufficiency, including those on dialysis, no adjustment of the initial dose is required.
Reducing the risk of cardiovascular morbidity and mortality in patients witharterial hypertension and left ventricular hypertrophy. The standard initial dose of losartan is 50 mg 1 time per day.
Store in a cool and dark place, protected from light and moisture, at a temperature not higher than 25 ° C.